MedTrace Logo

Imaging of Solid Tumors Using FAP-2286

NCT04621435 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 191

Last updated 2025-12-31

No results posted yet for this study

Summary

This is a multi-arm prospective trial that evaluates the ability of a novel imaging radiolabeled agents to detect metastatic cancer in participants with solid tumors using a gallium 68 (68Ga-) or copper 64 (64Cu-) FAP-2286 tracer. FAP-2286 is a peptidomimetic molecule that that binds to Fibroblast Activation Protein (FAP). FAP is a transmembrane protein expressed on cancer-associated fibroblasts, and has been shown to be present on a number of solid tumors.

Conditions

Interventions

DRUG

Gallium-68 labelled (68Ga-) FAP-2286

The dose will be 3 to 8 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging

PROCEDURE

Positron Emission Tomography (PET) imaging

Participants will be scanned for approximately 30 to 45 minutes

DRUG

Copper-64 labeled (64Cu-) FAP-2286

The dose will be 3.5 to 5.5 millicurie (mCi) +/- 10% given intravenously at a single time prior to imaging

Sponsors & Collaborators

  • Society of Abdominal Radiology

    collaborator OTHER

  • Thomas Hope

    lead OTHER

Principal Investigators

  • Thomas Hope, MD · University of California, San Francisco

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-14
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04621435 on ClinicalTrials.gov